Sermorelin is a GHRH peptide once FDA-approved as Geref, now compounded. What the evidence and its regulatory history say, why it's WADA-banned in sport, and what to ask clinics that reference it. This page is informational and does not diagnose, prescribe, or recommend therapies.
Looking for clinics by city? Explore peptide clinics in Miami , Los Angeles, and New York to compare verified providers by treatment focus.
Recovery peptide users often compare BPC-157 and TB-500, while metabolic health users usually cross-reference semaglutide.
Growth-hormone users often move between peptide research and provider discovery. Use the matching tool to narrow the right clinic path, or browse peptide clinics directly if you want to compare locations first.
Sermorelin pages attract users comparing growth-hormone and longevity options. The strongest clinics are clear about its once-approved-now-compounded status, run proper baseline testing, and explain the evidence honestly.
This page is useful for people researching hormone-optimisation, anti-aging, and longevity clinics that reference sermorelin within a supervised programme.
Sermorelin pricing usually sits within a wider hormone or longevity programme. Compare the diagnostics, oversight, and follow-up included, not just the monthly figure.
Sermorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that prompts the pituitary gland to release more of the body's own growth hormone. It has a distinctive regulatory history: it was FDA-approved as Geref in 1997, then voluntarily discontinued by its manufacturer and had its approval withdrawn in 2009 — the FDA noted the withdrawal was not for reasons of safety or effectiveness, but commercial ones. Today sermorelin is available mainly as a compounded medication prepared by licensed pharmacies; compounded products are not FDA-reviewed as finished goods. In the UK the MHRA treats it as unlicensed. It also sits on the WADA prohibited list. On clinic directories it appears in hormone-optimisation, anti-aging, and longevity contexts.
As a GHRH analogue, sermorelin stimulates the body's natural, pulsed release of growth hormone rather than supplying growth hormone directly, which clinics often present as a more 'physiological' approach. It is important to note that marketing often outpaces large long-term human outcome trials, so a provider should explain the realistic evidence. For someone comparing clinics, the useful questions are about baseline testing, supervision, and how response is monitored — not mechanism language.
Sermorelin is usually priced within a broader hormone-optimisation or longevity programme that includes consultation, diagnostics, and follow-up. Because it is compounded, sourcing quality and clinician oversight matter as much as the headline cost. See the peptide therapy cost guide.
Sermorelin should only be used under licensed clinical supervision with appropriate baseline testing and monitoring. While it has a relatively stronger history than many compounded peptides, compounded products are not FDA-reviewed as finished goods, and long-term outcome evidence in healthy adults is limited. It is also banned in tested sport. This page does not recommend sermorelin and does not provide dosing or administration guidance.
Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.
Not currently. Sermorelin was FDA-approved as Geref in 1997, but the approval was withdrawn in 2009 after the manufacturer discontinued it for commercial — not safety — reasons. Today it is available mainly as a compounded medication, which is not FDA-reviewed as a finished product.
No. Sermorelin is a GHRH analogue that prompts your body to release its own growth hormone, rather than supplying growth hormone directly. Clinics often frame this as a more physiological approach, but it still requires medical supervision.
Yes. Sermorelin is on the WADA prohibited list as a growth-hormone-releasing hormone / secretagogue, prohibited at all times. Any athlete subject to testing should treat it as banned.
Sermorelin is not licensed as a finished medicine in the UK; the MHRA treats it as unlicensed. Any clinical use sits under unlicensed-medicine rules and the prescribing clinician's responsibility.
In clinics it is usually discussed within hormone-optimisation, anti-aging, and longevity programmes aimed at supporting the body's own growth-hormone output. Evidence for broad anti-aging benefits in healthy adults is limited, so realistic expectations matter.
No. Peptide Clinic Finder is an informational directory. We do not sell sermorelin, provide medical advice, or recommend its use — we help you compare how clinics position and supervise treatments so you can make an informed decision with a licensed clinician.
Related comparisons: Semaglutide vs Sermorelin, Tirzepatide vs Sermorelin, CJC-1295 vs Sermorelin, HGH vs Sermorelin, Ipamorelin vs Sermorelin, Sermorelin vs Tesamorelin.
Next step
If you are considering this treatment, compare providers, review your options, and choose the path that best fits your goals and preferred level of care.
Move from peptide research into clinic comparisons, guides, and matching.
Not sure whether local clinics or online options are the better fit? compare providers or use our matching tool to find the right next step. If you want a broader market view first, find a peptide clinic near you.
Move from treatment research into provider comparison by choosing the next step that fits your buying journey. Some users want to compare programmes first, while others want a faster route into matched options or local clinic discovery.
Next step
Move from peptide research into real provider comparison by checking city pages, cost context, and related treatment comparisons. Clinics vary more by oversight and programme structure than by peptide name alone.
For clinics
Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.